Quarterly Assessment of Short-Acting β₂-Adrenergic Agonist Use as a Predictor of Subsequent Health Care Use for Asthmatic Patients in the United States

References

• Mannino D, Homa D, Akinbami L, Moorman J, Gwynn C, Redd S. Surveillance for asthma—United States, 1980–1999. MMWR Surveill Summ 2002; 51:1–13.
   PubMed Web of Science ®Google Scholar
• Rodrigo G, Rodrigo C, Hall J. Acute asthma in adults: a review. Chest 2004; 125:1081–1102.
   PubMed Web of Science ®Google Scholar
• Kamble S, Bharmal M. Incremental direct expenditure of treating asthma in the United States. J Asthma 2009; 46:73–80.
   PubMed Web of Science ®Google Scholar
• Malone D, Lawson K, Smith D. Asthma: an analysis of high-cost patients. Pharm Pract Manag Q 2000; 20:12–20.
   PubMedGoogle Scholar
• National Asthma Education and Prevention Program (NAEPP) Expert Panel. National Asthma Education and Prevention Program (NAEPP) expert panel report 3: guidelines for the diagnosis and management of asthma. J Allergy Clin Immunol 2007; 120:S94–S138.
   Google Scholar
• Donahue J, Weiss S, Livingston J, Goestch M, Greineder D, Platt R. Inhaled steroids and the risk of hospitalization for asthma. JAMA 1997; 277:887–891.
   PubMed Web of Science ®Google Scholar
• Senthilselvan A, Lawson J, Rennie D, Dosman J. Regular use of corticosteroids and low use of short-acting β2 -agonists can reduce asthma hospitalization. Chest 2005; 127:1242–1251.
   PubMed Web of Science ®Google Scholar
• Smith M, Rascati K, Barner J. A descriptive analysis of asthma-related medical services and prescription utilization among recipients in a Medicaid program. J Asthma 2005; 42:447–453.
   PubMed Web of Science ®Google Scholar
• Joint Task Force on Practice Parameters, American Academy of Allergy, Asthma and Immunology, American College of Allergy, Asthma, and Immunology and Joint Council of Allergy, Asthma and Immunology. Attaining optimal asthma control: a practice parameter. J Allergy Clin Immunol 2005; 116:S3–S11.
   PubMed Web of Science ®Google Scholar
• Stoloff S, Boushey H. Severity, control, and responsiveness in asthma. J Allergy Clin Immunol 2006; 117:544–548.
   PubMed Web of Science ®Google Scholar
• Juniper E, O’Byrne P, Guyatt G, Ferrie P, King D. Development and validation of a questionnaire to measure asthma control. Eur Respir J 1999; 14:902–907.
   PubMed Web of Science ®Google Scholar
• Nathan R, Sorkness C, Kosinski M, Schatz M, Li J, Marcus P. Development of the asthma control test: a survey for assessing asthma control. J Allergy Clin Immunol 2004; 113:59–65.
   PubMed Web of Science ®Google Scholar
• Vollmer W, Markson L, O’Connor E, Sanocki L, Fitterman L. Association of asthma control with health care utilization and quality of life. Am J Resp Crit Care Med 1999; 160:1647–1652.
   PubMed Web of Science ®Google Scholar
• Watson L, Kerstjens H, Rabe K, Kiri V, Visick G, Postma D. Obtaining optimal control in mild asthma: theory and practice. Fam Pract 2005; 22:305–310.
   PubMedGoogle Scholar
• Schatz M, Nakahiro R, Crawford W, Mendoza G, Mosen D, Stibolt T. Asthma quality-of-care markers using administrative data. Chest 2005; 128:1968–1973.
   PubMed Web of Science ®Google Scholar
• Schatz M, Zeiger R, Vollmer W, Mosen D, Apter A. Development and validation of a medication intensity scale derived from computerized pharmacy data that predicts emergency hospital utilization for persistent asthma. Am J Manag Care 2006; 12:478–484.
   PubMed Web of Science ®Google Scholar
• Schatz M, Zeiger R, Vollmer W, Mosen D, Cook E. Determinants of future long-term asthma control. J Allergy Clin Immunol 2006; 118:1048–1053.
   PubMed Web of Science ®Google Scholar
• Stempel D, McLaughin T, Stanford R, Fuhlbrigge A. Patterns of asthma control: a 3-year analysis of patient claims. J Allergy Clin Immunol 2005; 115:935–939.
   PubMed Web of Science ®Google Scholar
• Paris J, Peterson E, Wells K, Pladewell M, Burchard E, Choudhry S, Relationship between recent short-acting β-agonist use and subsequent asthma exacerbations. Ann Allergy Asthma Immunol 2008; 101:482–487.
   PubMed Web of Science ®Google Scholar
• Schatz M, Zeiger R, Vollmer W, Mosen D, Apter A. Validation of a beta-agonist long-term asthma control scale derived from computerized pharmacy data. J Allergy Clin Immunol 2006; 117:995–1000.
   PubMed Web of Science ®Google Scholar
• Glauber J, Fuhlbrigge A. Stratifying asthma populations by medication use: how you count counts. Ann Allergy Asthma Immunol 2002; 88:451–456.
   PubMedGoogle Scholar
• Chan J, Hui R, Spence M. Effects on resource utilization of adding salmeterol in combination or separately to inhaled corticosteroids. J Manag Care Pharm 2007; 13:21–27.
   PubMed Web of Science ®Google Scholar
• Diette G, Wu A, Skinner E, Markson L, Clark R. Treatment patterns among adult patients with asthma: factors associated with overuse of inhaled beta-agonists and underuse of inhaled corticosteroids. Arch Intern Med 1999; 159:2697–2704.
   PubMedGoogle Scholar
• Lynd L, Guh D, Pare P, Anis A. Patterns of inhaled asthma medication use: a 3-year longitudinal analysis of prescription claims data from British Columbia, Canada. Chest 2002; 122:1973–1981.
   PubMedGoogle Scholar
• O’Connor R, O’Donnell J, Pinto L, Wiener D, Legorreta A. Two-year retrospective economic evaluation of three dual-controller therapies used in the treatment of asthma. Chest 2002; 121:1028–1035.
   PubMed Web of Science ®Google Scholar
• Stempel D, Mauskopf J, McLaughin T, Yazdani C, Stanford R. Comparison of asthma costs in patients starting fluticasone propionate compared to patients starting montelukast. Respir Med 2001; 95:227–234.
   PubMed Web of Science ®Google Scholar
• Ten Brinke A, Sterk P, Masclee A, Spinhoven P, Schmidt J. Risk factors of frequent exacerbations in difficult-to-treat asthma. Eur Respir J 2005; 26:812–818.
   Google Scholar
• Markovitz B, Andresen E. Lack of insurance coverage and urgent care use for asthma: a retrospective cohort study. BMC Public Health 2006; 6:14.
   PubMed Web of Science ®Google Scholar